Paper39735331
CBX3 contributes to pancreatic adenocarcinoma progression via promoting KIF20A expression.
Wang X and 5 others. Cytotechnology, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. CBX3 contributes to pancreatic adenocarcinoma progression via promoting KIF20A expression. Papers, record 39735331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39735331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CBX3 contributes to pancreatic adenocarcinoma progression via promoting KIF20A expression.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35637952 | CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression. | Int J Biol Sci | 2022 | https://conductscience.org/library/papers/35637952 | PubMed |
| 2 | 32247999 | Immunotherapy for pancreatic cancer: A 2020 update. | Cancer Treat Rev | 2020 | https://conductscience.org/library/papers/32247999 | PubMed |
| 3 | 35172803 | Comprehensive pan-cancer analysis on CBX3 as a prognostic and immunological biomarker. | BMC Med Genomics | 2022 | https://conductscience.org/library/papers/35172803 | PubMed |
| 4 | 29678579 | CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. | Biochem Biophys Res Commun | 2018 | https://conductscience.org/library/papers/29678579 | PubMed |
| 5 | 36096734 | KDELR2-KIF20A axis facilitates bladder cancer growth and metastasis by enhancing Golgi-mediated secretion. | Biol Proced Online | 2022 | https://conductscience.org/library/papers/36096734 | PubMed |
| 6 | 34216688 | Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. | Cancer Lett | 2021 | https://conductscience.org/library/papers/34216688 | PubMed |
| 7 | 33116867 | CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses. | Cancer Manag Res | 2020 | https://conductscience.org/library/papers/33116867 | PubMed |
| 8 | 36173644 | A comprehensive review of pancreatic cancer and its therapeutic challenges. | Aging (Albany NY) | 2022 | https://conductscience.org/library/papers/36173644 | PubMed |
| 9 | 36830695 | Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. | Biomolecules | 2023 | https://conductscience.org/library/papers/36830695 | PubMed |
| 10 | 34785774 | Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma. | Oncogene | 2022 | https://conductscience.org/library/papers/34785774 | PubMed |
| 11 | 38125441 | FOXM1/KIF20A axis promotes clear cell renal cell carcinoma progression via regulating EMT signaling and affects immunotherapy response. | Heliyon | 2023 | https://conductscience.org/library/papers/38125441 | PubMed |
| 12 | 34002083 | Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. | Nat Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34002083 | PubMed |
| 13 | 37674204 | CBX3 promotes clear cell renal carcinoma through PI3K/AKT activation and aberrant immunity. | J Transl Med | 2023 | https://conductscience.org/library/papers/37674204 | PubMed |
| 14 | 36798768 | Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer. | Heliyon | 2023 | https://conductscience.org/library/papers/36798768 | PubMed |
| 15 | 23313480 | Heterochromatin protein 1γ overexpression in P19 embryonal carcinoma cells elicits spontaneous differentiation into the three germ layers. | Biochem Biophys Res Commun | 2013 | https://conductscience.org/library/papers/23313480 | PubMed |
| 16 | 36923407 | Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer. | Front Immunol | 2023 | https://conductscience.org/library/papers/36923407 | PubMed |
| 17 | 35280819 | An Integrated Pan-Cancer Analysis of ADAMTS12 and Its Potential Implications in Pancreatic Adenocarcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35280819 | PubMed |
| 18 | 37489138 | Advances and Prospects in the Treatment of Pancreatic Cancer. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/37489138 | PubMed |
| 19 | 34796785 | PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis. | Channels (Austin) | 2021 | https://conductscience.org/library/papers/34796785 | PubMed |
| 20 | 36842769 | Liquid biopsy in pancreatic cancer - Current perspective and future outlook. | Biochim Biophys Acta Rev Cancer | 2023 | https://conductscience.org/library/papers/36842769 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CBX3 | 11335 | PubTator's text mining | https://conductscience.org/library/genes/11335 | NCBI Gene |
| KIF20A | 10112 | PubTator's text mining | https://conductscience.org/library/genes/10112 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39735331
GET https://conductscience.org/api/papers/v1/39735331/references?page=2